
    
      This is a modified-blind, randomized, placebo-controlled, multicenter, parallel-group trial
      of levalbuterol HFA MDI administered using a facemask and holding chamber in subjects birth
      to <48 months with asthma. This study was previously posted by Sepracor Inc. In October 2009,
      Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's
      name was changed to Sunovion Pharmaceuticals Inc.
    
  